Axogen (AXGN) on Monday reported preliminary Q4 revenue of about $59.9 million, up 21.3% from a year earlier.
Analysts surveyed by FactSet are expecting Q4 revenue of $58 million.
The company said the increase was driven by targeting high-potential accounts in extremities and head & neck procedures, wider adoption of its peripheral nerve surgical algorithm, and increased use of Resensation in post-mastectomy breast reconstruction.
As of Dec. 31, Axogen reported cash, cash equivalents, restricted cash, and investments of roughly $45.5 million.
Axogen shares were 1.4% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments